Crescent Biopharma, Inc. (CBIO) AI Stock Analysis

Crescent Biopharma, Inc., formerly known as GlycoMimetics, Inc., is a Waltham, Massachusetts-based biotechnology company founded in 2024 with 69 employees. The company researches and develops cancer therapy candidates in the United States. Its clinical pipeline is led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody currently in a Phase 3 clinical trial designed to treat solid tumors. Crescent Biopharma is also developing candidates CR-002 and CR-003. Additionally, the company maintains a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics.

Annual revenue was $10.2M in FY2020, before dropping to $1.2M in FY2021, $75,000 in FY2022, and $10,000 in FY2023. In FY2025, revenue rebounded to $10.8M, representing revenue growth of 108340.0%, while research and development expenses reached $138.1M. Operating margin in FY2025 was -1407.5%, and net income stood at -$153.9M, or -$27.49 per share. Over the trailing twelve months ended June 30, 2026, revenue totaled $11.9M with an operating margin of -1432.6% and diluted earnings per share of -$7.63. The company maintained a gross margin of 100.0% across all reported fiscal years.

As of June 30, 2026, Crescent Biopharma held $171.6M in cash and short-term investments alongside total debt of $1.4M, resulting in net cash of $170.2M. Total assets stood at $182.8M against shareholders' equity of $163.3M, supported by a current ratio of 9.66 and a debt-to-equity ratio of 0.01. During FY2025, operating cash flow was -$71.5M, free cash flow was -$144.5M, and capital expenditures were $72.9M, while share buybacks totaled $177,000.

At a last close of $11.84 on October 16, 2026, Crescent Biopharma carried a market capitalization of $439.8M and an enterprise value of $361.0M. The stock traded at a price-to-sales multiple of 37.0x and an EV-to-revenue multiple of 30.4x, well above the US-listed Healthcare median price-to-sales ratio of 4.1x. Its price-to-book multiple stood at 3.3x. Over the past year, the stock fell 4.1%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock declined 94.0%, trailing the S&P 500 benchmark gain of 83.0%.

Wall Street coverage consists of 7 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $31.50, implying an upside of 166.0% from the last close of $11.84. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.7M and an EPS of -$2.35. Crescent Biopharma beat earnings per share estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Crescent Biopharma, Inc. (CBIO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CBIO income statement, CBIO balance sheet, CBIO key metrics, CBIO analyst forecast, CBIO chart. See the CBIO stock overview for the latest quote and news.